Skip to content
Riskpilot
← Back to search
Sign in
Sign in
Get full access
Oncosyne AS
AS
Active
Org 926191942
Ullernchausséen 64, 0379
Oslo
Research and experimental development on natural sciences and engineering
·
NACE 7210
Est. 2020 · 5 years old
6 employees
Monitor
Share
Norway
/
Companies
/
Research and experimental development on natural sciences and engineering
/
Oncosyne AS
Overview
Financials
People & ownership
Related companies
Loading company…
People & ownership
Management
Actively employed in the business
Name
Role
Member since
Former (1)
BT
Bengt Thomas Andersson
Observer
Observer
2023 – 2026
Board of directors
Non-executive oversight
Name
Role
Member since
Current (5)
PA
Peter Andreas Wold Eide
Chairman
Chairman
2023
JE
John Edvard Karlsrud
Board of Directors
Board of Directors
2023
JM
Janne Merethe Nestvold
Board of Directors
Board of Directors
2023
BO
Bjørn Olav Bakka
Board of Directors
Board of Directors
2025
SW
Svenn Widerberg
Board of Directors
Board of Directors
2023
Former (3)
SB
Ståle Bjørnstad
Board of Directors
Board of Directors
2024 – 2025
ØS
Øyvind Sverre Bruland
Board of Directors
Board of Directors
2022 – 2023
JB
Jarle Bruun
Shareholders
As of last annual report
Kaarstad Smier As — 31.12%
Norske Omveier As — 31.12%
Wibo Consulting As — 8.78%
Daedalus As — 6.35%
Startuplab Founders Fund Iv As — 5.93%
Millimedia As — 4.17%
Fortress Fund 1 As — 3.41%
Farvatn Venture As — 2.51%
Svarthøi Holding As — 1.84%
Jo Strømgren — 1.84%
Jalco Consulting As — 1.67%
99%
Shareholder
Type
Ownership
Votes
Since
Kaarstad Smier As
Company
31.12%
31.12%
2025
Norske Omveier As
Company
31.12%
31.12%
2025
Wibo Consulting As
Company
8.78%
8.78%
2025
Daedalus As
Company
6.35%
6.35%
2025
Startuplab Founders Fund Iv As
Company
5.93%
5.93%
2025
Millimedia As
Company
4.17%
4.17%
2025
Fortress Fund 1 As
Company
3.41%
3.41%
2025
Farvatn Venture As
Company
2.51%
2.51%
2025
Svarthøi Holding As
Company
1.84%
1.84%
2025
Jo Strømgren
Individual
1.84%
1.84%
2025
Jalco Consulting As
Company
1.67%
1.67%
2025
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive.
Learn more
.
More on Oncosyne AS
Overview →
Headline figures, risk assessment and company summary
Financials & key figures →
Revenue, EBITDA, balance sheet and 5-year trend
Related companies →
Corporate hierarchy, parent and subsidiary network
Deputy Chairman
Deputy Chairman
2022 – 2022